Media Inquiries

If you are interested in interviewing a CCR scientist, OR you are a scientist who has been contacted by a member of the media, please contact the NCI Press Office at ncipressofficers@mail.nih.gov or by phone at 240.760.6600.

News and Events

Celebrating CCR Careers: Alan Rein, Ph.D.

Alan Rein, Ph.D., is a known expert in the field of viral assembly, particularly in retroviruses like the human immunodeficiency virus (HIV). After an extensive career studying molecular mechanisms of retroviral replication and pathogenesis, he has announced his retirement.

Living with and learning about neuroendocrine tumors: A conversation with Dr. Jaydira Del Rivero

Jaydira Del Rivero, M.D., Assistant Research Physician in the Developmental Therapeutics Branch, studies neuroendocrine tumors – a rare group of malignant neoplasms that originates from neuroendocrine cells and affects almost any part of the body. In this Q&A, Dr. Del Rivero and a natural history trial participant discuss an ongoing neuroendocrine study and their experiences at NIH.

Following the fellowship experience with CCR fellow Bailey Johnson

Bailey Johnson is a postbaccalaureate fellow in the Laboratory of Cell Biology. For this Black History Month Q&A, we asked her about her research journey, personal goals and advice for the next generation of students of color.

Clinical trial evaluates drug for treatment of neurofibromatosis type 1 and atypical neurofibromas

Up to half of the people with neurofibromatosis type 1 develop plexiform neurofibromas (PNs), tumors that grow along nerves. Over time, PNs may transform into atypical neurofibromas (ANFs) and then into cancerous tumors. Andrea Gross, M.D., Assistant Research Physician in the Pediatric Oncology Branch, is leading a study of a drug, abemaciclib, to treat ANFs in children.

Clinical trial compares interval dosing of two immune checkpoint inhibitors

William D. Figg Sr., Pharm.D., Deputy Chief of the Genitourinary Malignancies Branch, is leading CCR’s efforts in a multi-institution, international study comparing methods of dosing nivolumab and pembrolizumab. This study is intended for people who have advanced or metastatic cancer that has not been previously treated with an immune checkpoint inhibitor.

3D illustration proteins with lymphocytes , T cells or cancer cells

Unique gene expression profiles identify rare T cells that could be effective in cancer immunotherapy

CCR researchers led by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, have found unique expression profiles in 50 genes that help identify rare anti-tumor lymphocytes that can be used as personalized immunotherapy in many patients with metastatic solid tumors.

Scans of a woman with breast cancer before and after TIL therapy.

NCI study advances personalized immunotherapy for metastatic breast cancer

An experimental form of immunotherapy that uses an individual’s own tumor-fighting immune cells could potentially be used to treat people with metastatic breast cancer, according to results from an ongoing clinical trial led by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch.

All about the drive: A rare kidney cancer meets its match at NIH

On New Year’s Eve, 2020, Katie Coleman was diagnosed with a very rare form of advanced kidney cancer. She enrolled in a clinical trial led by a collaborative CCR team that gave her the opportunity to have surgery in hopes of removing her tumors.

Cartoon illustration showing how a variety of cell types surround and interact with cancer cells

Researchers develop new method to estimate cell-type-specific information from bulk tumor data

CCR researchers have established a way to extract cell-type-specific expression information from bulk gene expression data of a tumor sample. Their computational approach, which outperforms comparable state-of-the-art methods, evaluates thousands of tumor samples with minimal cost.

Breast cancer stem cells become aggressive upon contact with macrophages

New findings suggest that breast cancer cells gain stem-like characteristics of invasiveness, aggressiveness and drug resistance upon contact with macrophages, specialized white blood cells in the immune system.

A high-fiber diet may improve the response of melanoma patients to immunotherapy

A new study co-led by Giorgio Trinchieri, M.D., chief of the Laboratory of Integrative Cancer Immunology, found that a diet rich in fiber may help some people being treated for melanoma respond to immunotherapy treatment by influencing the gut microbiome. The new findings come from an analysis of people with melanoma and mouse models of the disease.

Breadcrumb

News and Events